Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS.

Ravenscroft TA, Baker MC, Rutherford NJ, Neumann M, Mackenzie IR, Josephs KA, Boeve BF, Petersen R, Halliday GM, Kril J, van Swieten JC, Seeley WW, Dickson DW, Rademakers R.

Neurobiol Aging. 2013 Sep;34(9):2235.e11-3. doi: 10.1016/j.neurobiolaging.2013.04.004. Epub 2013 Apr 28.

2.

Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS.

Dormann D, Madl T, Valori CF, Bentmann E, Tahirovic S, Abou-Ajram C, Kremmer E, Ansorge O, Mackenzie IR, Neumann M, Haass C.

EMBO J. 2012 Nov 14;31(22):4258-75. doi: 10.1038/emboj.2012.261. Epub 2012 Sep 11.

3.

FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.

Neumann M, Bentmann E, Dormann D, Jawaid A, DeJesus-Hernandez M, Ansorge O, Roeber S, Kretzschmar HA, Munoz DG, Kusaka H, Yokota O, Ang LC, Bilbao J, Rademakers R, Haass C, Mackenzie IR.

Brain. 2011 Sep;134(Pt 9):2595-609. doi: 10.1093/brain/awr201. Epub 2011 Aug 19.

4.

Protein arginine methyltransferase 1 and 8 interact with FUS to modify its sub-cellular distribution and toxicity in vitro and in vivo.

Scaramuzzino C, Monaghan J, Milioto C, Lanson NA Jr, Maltare A, Aggarwal T, Casci I, Fackelmayer FO, Pennuto M, Pandey UB.

PLoS One. 2013 Apr 19;8(4):e61576. doi: 10.1371/journal.pone.0061576. Print 2013.

5.

Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations.

Tradewell ML, Yu Z, Tibshirani M, Boulanger MC, Durham HD, Richard S.

Hum Mol Genet. 2012 Jan 1;21(1):136-49. doi: 10.1093/hmg/ddr448. Epub 2011 Sep 28.

6.

Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.

Neumann M, Valori CF, Ansorge O, Kretzschmar HA, Munoz DG, Kusaka H, Yokota O, Ishihara K, Ang LC, Bilbao JM, Mackenzie IR.

Acta Neuropathol. 2012 Nov;124(5):705-16. doi: 10.1007/s00401-012-1020-6. Epub 2012 Jul 28.

PMID:
22842875
7.

Fused in sarcoma (FUS): an oncogene goes awry in neurodegeneration.

Dormann D, Haass C.

Mol Cell Neurosci. 2013 Sep;56:475-86. doi: 10.1016/j.mcn.2013.03.006. Epub 2013 Apr 2. Review.

PMID:
23557964
8.

Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS.

Suárez-Calvet M, Neumann M, Arzberger T, Abou-Ajram C, Funk E, Hartmann H, Edbauer D, Kremmer E, Göbl C, Resch M, Bourgeois B, Madl T, Reber S, Jutzi D, Ruepp MD, Mackenzie IR, Ansorge O, Dormann D, Haass C.

Acta Neuropathol. 2016 Apr;131(4):587-604. doi: 10.1007/s00401-016-1544-2. Epub 2016 Feb 19.

PMID:
26895297
9.

FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis.

Broustal O, Camuzat A, Guillot-Noël L, Guy N, Millecamps S, Deffond D, Lacomblez L, Golfier V, Hannequin D, Salachas F, Camu W, Didic M, Dubois B, Meininger V, Le Ber I, Brice A; French clinical and genetic research network on FTD/FTD-MND.

J Alzheimers Dis. 2010;22(3):765-9.

PMID:
21158017
10.
11.

The effect of PRMT1-mediated arginine methylation on the subcellular localization, stress granules, and detergent-insoluble aggregates of FUS/TLS.

Yamaguchi A, Kitajo K.

PLoS One. 2012;7(11):e49267. doi: 10.1371/journal.pone.0049267. Epub 2012 Nov 13.

12.

FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis.

Mackenzie IR, Neumann M.

Brain Res. 2012 Jun 26;1462:40-3. doi: 10.1016/j.brainres.2011.12.010. Epub 2011 Dec 13. Review.

PMID:
22261247
13.

Frontotemporal lobar degeneration: diversity of FTLD lesions.

Seilhean D, Bielle F, Plu I, Duyckaerts C.

Rev Neurol (Paris). 2013 Oct;169(10):786-92. doi: 10.1016/j.neurol.2013.07.015. Epub 2013 Sep 12. Review.

PMID:
24035575
14.

FUS pathology in basophilic inclusion body disease.

Munoz DG, Neumann M, Kusaka H, Yokota O, Ishihara K, Terada S, Kuroda S, Mackenzie IR.

Acta Neuropathol. 2009 Nov;118(5):617-27. doi: 10.1007/s00401-009-0598-9. Epub 2009 Oct 15.

PMID:
19830439
15.

FUS-mediated alternative splicing in the nervous system: consequences for ALS and FTLD.

Orozco D, Edbauer D.

J Mol Med (Berl). 2013 Dec;91(12):1343-54. doi: 10.1007/s00109-013-1077-2. Epub 2013 Aug 24. Review.

PMID:
23974990
16.

Pathological features of FTLD-FUS in a Japanese population: analyses of nine cases.

Kobayashi Z, Kawakami I, Arai T, Yokota O, Tsuchiya K, Kondo H, Shimomura Y, Haga C, Aoki N, Hasegawa M, Hosokawa M, Oshima K, Niizato K, Ishizu H, Terada S, Onaya M, Ikeda M, Oyanagi K, Nakano I, Murayama S, Akiyama H, Mizusawa H.

J Neurol Sci. 2013 Dec 15;335(1-2):89-95. doi: 10.1016/j.jns.2013.08.035. Epub 2013 Sep 4.

PMID:
24050818
17.

No association of PGRN 3'UTR rs5848 in frontotemporal lobar degeneration.

Rollinson S, Rohrer JD, van der Zee J, Sleegers K, Mead S, Engelborghs S, Collinge J, De Deyn PP, Mann DM, Van Broeckhoven C, Pickering-Brown SM.

Neurobiol Aging. 2011 Apr;32(4):754-5. doi: 10.1016/j.neurobiolaging.2009.04.009. Epub 2009 May 14.

PMID:
19446372
18.

The presence of heterogeneous nuclear ribonucleoproteins in frontotemporal lobar degeneration with FUS-positive inclusions.

Gami-Patel P, Bandopadhyay R, Brelstaff J, Revesz T, Lashley T.

Neurobiol Aging. 2016 Jul 15;46:192-203. doi: 10.1016/j.neurobiolaging.2016.07.004. [Epub ahead of print]

PMID:
27500866
19.

Transportin1: a marker of FTLD-FUS.

Brelstaff J, Lashley T, Holton JL, Lees AJ, Rossor MN, Bandopadhyay R, Revesz T.

Acta Neuropathol. 2011 Nov;122(5):591-600. doi: 10.1007/s00401-011-0863-6. Epub 2011 Aug 17.

PMID:
21847626
20.

EWS is a substrate of type I protein arginine methyltransferase, PRMT8.

Kim JD, Kako K, Kakiuchi M, Park GG, Fukamizu A.

Int J Mol Med. 2008 Sep;22(3):309-15.

PMID:
18698489
Items per page

Supplemental Content

Write to the Help Desk